

## **Companion Diagnostics: Technologies and Markets**

Market Research Report | 2024-04-23 | 121 pages | BCC Research

### **AVAILABLE LICENSES:**

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

### **Report description:**

Description

Report Scope

The current report provides detailed coverage of the companion diagnostics market. This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints, and challenges in the market. The report details the companion diagnostics market share based on product and service, type of test, technology, and application. The market's products and services is segmented into instruments, consumables, and services. It is categorized based on the type of test into commercial CDx and lab-developed tests (LDT)-CDx. Based on technology, the market is segmented into polymerase chain reaction, immunohistochemistry, next-generation sequencing, in situ hybridization, genotyping, immunoassays, exosomes, others, and services market. Based on application, the CDx market is categorized into cancer, neurologic disorders, cardiovascular disease, infectious disease, and others. Based on end users, the companion diagnostics market is segmented into clinical laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users. The report also includes company profiles of the major players in the companion diagnostics market, with details about each company's business segments, financials, product portfolios, and recent developments.

By geographical region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The North America region includes the U.S. and Canada; Europe includes Germany, the U.K., Italy, France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2020 and 2021 as the historic years, 2022 as the base year, and 2028 as the forecast year.

Report Includes

- 54 data tables and 59 additional tables
- Overview and an analysis of the global markets for companion diagnostics (CDx).
- Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028.
- A look at the current and future market potential of companion diagnostics along with the market dynamics, competitive

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

landscape and regulatory scenario.

- Estimate of the market size and revenue forecast for the global CDx market, and corresponding market share analysis based on product and services, test type, technology, application, end user and region.
- Discussion of the market opportunities for CDx products by identification of high-growth applications in different therapeutic areas, with a focus on the largest and fastest-expanding markets for diseases.
- Analysis of recent market developments and clinical trials, as well as the leading companies engaged in R&D and product developments in CDx reagents.
- Discussion of the importance of ESG in the CDx industry, including consumer attitudes, the impact of ESG on company performance, ESG score analysis, and ESG practices followed by leading companies.
- Review of key patent grants and patent applications related to CDx.
- Identification of the major vendors along with an analysis of the competitive intelligence, including companies' market shares, recent M&A activity, and venture funding outlook.
- Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and QIAGEN

## Executive Summary

Summary:

The global market for companion diagnostics is estimated to increase from \$7.6 billion in 2023 to reach \$15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.

## Table of Contents:

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Highlights of the Market for Companion Diagnostics (CDx)
Chapter 2 Market Overview
Introduction
History
Regulatory Landscape
Companion Diagnostics Regulations in the U.S.
Companion Diagnostics Regulations Outside the U.S.
LDT-CDx Regulation
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Market Restraints
Market Opportunities
Market Challenges
Chapter 4 Emerging Technologies and Developments
Emerging Technologies
Multiplex Testing
Next-Generation Sequencing (NGS)
Digital PCR
Liquid Biopsy

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Artificial Intelligence  
Chapter 5 Market Segmentation Analysis  
Segmental Breakdown  
Global Market for Companion Diagnostics by Product and Service  
Market Share and Forecast  
Instruments  
Consumables  
Services  
Global Market for Companion Diagnostics by Type of Test  
Market Share and Forecast  
LDT-CDx  
Commercial CDx  
Global Market for Companion Diagnostics by Technology  
Market Share and Forecast  
Polymerase Chain Reaction  
Immunohistochemistry  
Next-Generation Sequencing  
In Situ Hybridization  
Genotyping  
Immunoassays  
Exosomes  
Others  
Services  
Global Market for Companion Diagnostics by Application  
Market Share and Forecast  
Cancer  
Market for the Application of CDx in Cancer by Type  
Neurologic Disorders  
Cardiovascular Disease  
Infectious Diseases  
Other Diseases  
Market Breakdown by End User  
Market Share and Forecast  
Clinical Laboratories  
Pharmaceutical Companies  
Contract Research Organizations (CROs)  
Other End Users  
Geographic Breakdown  
Global Market for Companion Diagnostics by Region  
North America  
The U.S.  
Canada  
Europe  
Germany  
The U.K.  
France  
Italy

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Rest of Europe  
Asia-Pacific  
China  
Japan  
India  
Rest of Asia-Pacific  
Rest of the World  
Chapter 6 Competitive Intelligence  
Market Share Analysis  
Leading Market Players in Companion Diagnostics Market, by Technology  
Grants and Funding in Companion Diagnostics  
Recent Developments of Key Market Players  
Clinical Trials Analysis  
Clinical Trials Analysis, by Type of Study  
Clinical Trials Analysis, by Status  
Clinical Trials Analysis, by Phase  
Clinical Trials Analysis, by Region  
Patent Analysis  
Patents, by Year  
Patents, by Top Applicant  
Patents, by Top Owner  
Patents, by Jurisdiction  
Chapter 7 Sustainability in Companion Diagnostics: ESG Perspective  
Introduction to ESG  
Sustainability in the Companion Diagnostics Industry: An ESG Perspective  
Key ESG Issues  
Concluding Remarks from BCC  
Chapter 8 Appendix  
Methodology  
References  
Company Profiles  
ABBOTT  
AGILENT TECHNOLOGIES INC.  
ARUP LABORATORIES  
BIOMERIEUX  
DANAHER CORP.  
F. HOFFMANN-LA ROCHE LTD.  
ILLUMINA INC.  
MYRIAD GENETICS INC.  
QIAGEN  
THERMO FISHER SCIENTIFIC INC.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Companion Diagnostics: Technologies and Markets**

Market Research Report | 2024-04-23 | 121 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

